Regulation of In Vivo CAR‑T Therapies
Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…
China Drug Regulation Updates 2026
China Drug Regulation Updates 2026 – Strategic Implications for International Biopharma and MedTech China has recently updated the implementing regulations under its Drug Administration Law. The changes reflect a continued shift toward encouraging pharmaceutical innovation while strengthening regulatory oversight across the full product lifecycle. On January 27, 2026, the State Council promulgated the revised “Regulations for the…
TGA Provisional Registration Pathway Australia
TGA Provisional Registration: Accelerating Patient Access to Medicines in Australia In Australia, the Therapeutic Goods Administration (TGA) offers a provisional registration pathway for prescription medicines. This pathway enables earlier patient access to certain promising new medicines, based on preliminary clinical data. In other markets, comparable processes may be known as conditional approval, or similar. Eligible…
Australia and the ACCESS Consortium: Navigating Regulatory Collaboration
The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…
Choosing the Right Regulatory Affairs Consultant
Whether you are part of an established team, a start-up, an SME, or a founder, navigating the stringent requirements of the Medical Technology, Biotechnology, and Pharmaceutical (MTP) sectors can be complex and challenging. This is where partnering with the right Regulatory Affairs Consultant becomes invaluable. Understanding the Role of a Regulatory Affairs Consultant A regulatory…
How to Register a Medicine in Australia
Six ways to register a medicine in Australia: Understanding the complexities of medicine registration. In the dynamic landscape of pharmaceuticals, securing registration for a new medicine requires a nuanced understanding of regulatory procedures and individual client needs. The process involves meticulous planning and strategic vision to ensure successful registration. However, beyond the intricacies of registration,…
Navigating the Hong Kong Medicines Regulatory System
The Year of the Dragon stands as a fitting emblem for Hong Kong’s medicines regulatory system, symbolising strength, resilience, and vigilant oversight
The Adjutor Healthcare Group Expands Global Presence with the Establishment of Adjutor Healthcare Hong Kong
Today marks a significant milestone for the Adjutor Healthcare Group, as we proudly announce the establishment of Adjutor Healthcare Hong Kong, further solidifying our commitment to excellence supporting global healthcare, development, regulatory and commercialisation needs.
Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.